Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 3Lymphoid 3Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ispinesib × Breast × Clear all
NCT00607841 2019-05-06

A Study of Ispinesib in Metastatic Breast Cancer

Cytokinetics

Phase 1 Terminated
16 enrolled
Breast

Breast Neoplasms

NCT00089973 2018-02-26

Study Of Ispinesib In Subjects With Breast Cancer

GlaxoSmithKline

Phase 2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡